Tretazicar (Standard)

Tretazicar (Standard) is the analytical standard of Tretazicar. This product is intended for research and analytical applications. Tretazicar (CB 1954), an antitumor proagent, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD (P) H:quinone oxidoreductase 1 (NQO1) [1][2].

Product Specifications

CAS Number

[21919-05-1]

UNSPSC

12352100

Target

DNA Alkylator/Crosslinker; Reference Standards

Related Pathways

Cell Cycle/DNA Damage; Others

Field of Research

Cancer

Smiles

O=C(N)C1=CC(N2CC2)=C([N+]([O-])=O)C=C1[N+]([O-])=O

Molecular Formula

C9H8N4O5

Molecular Weight

252.18

References & Citations

[1]Knox RJ, et al. Bioactivation of 5- (aziridin-1-yl) -2,4-dinitrobenzamide (CB 1954) by human NAD (P) H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res. 2000 Aug 1;60 (15) :4179-86.|[2]Knox RJ, et al. CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des. 2003;9 (26) :2091-104.|[3]Green NK, et al. Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronicadenovirus vector. Int J Cancer. 2003 Mar 10;104 (1) :104-12.|[4]Drabek D, et al. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther. 1997 Feb;4 (2) :93-100.